← All companies ← MEC Manual MEI → ← MDXH Life Sciences Tools & Services MTD →
MEDP, Medpace Holdings
Medpace Holdings markets and Clinical Development Services Before a new drug can be commercialized, it often must undergo extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy.
We are one of the world's leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.
CROs provide a comprehensive range of product development services for Phase I-IV clinical trials.
The business
What it sells, where the money comes from, the kind of company it is.
Next report Est. 10/19–10/26 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~23 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- What it is
- Revenue is led by Oncology (30%) and Other (29%), with 4 more lines behind.
- What moves the needle
- Operating margin has run about 18% through the cycle, a solid margin the cost base and competition set as much as the price does. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has run high across the record (median 27%, above 15% in 6 of 9 years), though buybacks and expensed R&D and brands shrink the capital base, so the figure overstates the underlying economics. The steadier read is owner earnings: roughly 22% of revenue reaches owners as cash, consistently. Whether these returns reflect real pricing power or an accounting artifact is the judgment the 10-K is for.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 10-K →Revenue spreads across 6 lines, the largest Oncology at 30%.
- Oncology30%$748M
- Other29%$745M
- Other16%$409M
- AVAI10%$255M
- Cardiology9%$239M
- Cardiology5%$135M
From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $422M | $436M | $705M | $861M | $926M | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B | $2.8B | RevenueRevenue |
| 15% | 15% | 11% | 11% | 10% | 9% | 9% | 9% | 9% | 8% | 7% | SG&A / revenueSG&A/rev |
| $52M | $65M | $101M | $127M | $167M | $199M | $279M | $337M | $447M | $535M | $583M | Operating incomeOp. inc. |
| 12.5% | 14.9% | 14.3% | 14.8% | 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% | 21.0% | Operating marginOp. mgn |
| $22M | $57M | $94M | $125M | $169M | $202M | $283M | $336M | $476M | $542M | — | Pretax incomePretax |
| $13M | $39M | $73M | $100M | $145M | $182M | $245M | $283M | $404M | $451M | $492M | Net incomeNet inc. |
| 39% | 31% | 22% | 20% | 14% | 10% | 13% | 16% | 15% | 17% | 18% | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $92M | $97M | $157M | $202M | $259M | $263M | $388M | $433M | $609M | $713M | $753M | Operating cash flowOp. cash |
| $7M | $9M | $9M | $8M | $12M | $16M | $19M | $24M | $28M | $27M | $27M | DepreciationDeprec. |
| $61M | $45M | $68M | $72M | $88M | $51M | $102M | $106M | $151M | $200M | $213M | Working capital & otherWC & other |
| $14M | $12M | $16M | $18M | $31M | $28M | $37M | $37M | $37M | $31M | $46M | CapexCapex |
| 3.2% | 2.7% | 2.3% | 2.1% | 3.4% | 2.5% | 2.5% | 1.9% | 1.7% | 1.2% | 1.7% | Capex / revenueCapex/rev |
| $84M | $89M | $147M | $194M | $247M | $247M | $369M | $409M | $581M | $682M | $726M | Owner earningsOwner earn. |
| 20.0% | 20.4% | 20.9% | 22.5% | 26.7% | 21.6% | 25.3% | 21.7% | 27.5% | 26.9% | 26.1% | Owner earnings marginOE mgn |
| $78M | $86M | $141M | $184M | $227M | $235M | $351M | $397M | $572M | $682M | $707M | Free cash flowFCF |
| 18.5% | 19.6% | 19.9% | 21.4% | 24.6% | 20.6% | 24.1% | 21.0% | 27.1% | 26.9% | 25.4% | Free cash flow marginFCF mgn |
| $0 | $156M | $0 | $0 | $98M | $62M | $848M | $144M | $170M | $917M | — | BuybacksBuybacks |
| ($13M) | ($12M) | ($17M) | ($19M) | ($31M) | ($31M) | ($39M) | ($35M) | ($28M) | ($31M) | — | Investing cash flowInv. cash |
| ($58M) | ($98M) | ($142M) | ($74M) | ($82M) | ($44M) | ($776M) | ($183M) | ($154M) | ($860M) | — | Financing cash flowFin. cash |
| ($632K) | $2M | ($1M) | ($167K) | $666K | ($4M) | ($7M) | $1M | ($3M) | $6M | — | Exchange-rate effectFX |
| $20M | ($11M) | ($3M) | $109M | $146M | $184M | ($433M) | $217M | $424M | ($172M) | — | Change in cashΔ cash |
| 4% | 6% | 12% | 17% | 27% | 36% | 68% | 91% | 243% | — | — | ROICROIC |
| 2% | 8% | 12% | 14% | 18% | 19% | 64% | 51% | 49% | 98% | 113% | Return on equityROE |
| 2% | 8% | 12% | 14% | 18% | 19% | 64% | 51% | 49% | 98% | 113% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $37M | $26M | $23M | $132M | $278M | $461M | $28M | $245M | $669M | $497M | $503M | Cash & investmentsCash+inv |
| $80M | $83M | $133M | $156M | $161M | $186M | $253M | $298M | $296M | $402M | $442M | ReceivablesReceiv. |
| $11M | $17M | $17M | $22M | $27M | $26M | $33M | $32M | $33M | $28M | $38M | Accounts payablePayables |
| $69M | $66M | $117M | $133M | $134M | $161M | $220M | $267M | $264M | $374M | $404M | Operating working capitalOper. WC |
| $133M | $130M | $178M | $317M | $474M | $691M | $334M | $594M | $1.0B | $990M | $1.1B | Current assetsCur. assets |
| $169M | $193M | $263M | $343M | $440M | $557M | $803M | $925M | $1.1B | $1.3B | $1.4B | Current liabilitiesCur. liab. |
| 0.8× | 0.7× | 0.7× | 0.9× | 1.1× | 1.2× | 0.4× | 0.6× | 0.9× | 0.7× | 0.7× | Current ratioCurr. ratio |
| $44M | $49M | $38M | $47M | $85M | $93M | $110M | $121M | $124M | $131M | — | Net PP&ENet PP&E |
| $661M | $661M | $661M | $662M | $662M | $662M | $662M | $662M | $662M | $662M | $662M | GoodwillGoodwill |
| $979M | $951M | $1.0B | $1.1B | $1.4B | $1.7B | $1.4B | $1.7B | $2.1B | $2.0B | $2.1B | Total assetsAssets |
| $164M | $222M | $80M | $0 | — | — | — | — | — | — | $0 | Total debtDebt |
| $127M | $195M | $56M | ($132M) | — | — | — | — | — | — | ($503M) | Net debt / (cash)Net debt |
| $368M | $447M | $406M | $417M | $585M | $707M | $966M | $1.1B | $1.3B | $1.5B | — | Total liabilitiesTotal liab. |
| $611M | $509M | $599M | $726M | $806M | $953M | $386M | $559M | $826M | $459M | $434M | Shareholders’ equityEquity |
| 2.3% | 1.0% | 0.9% | 2.4% | 1.5% | 1.3% | 1.5% | 1.1% | 1.2% | 1.4% | 0.8% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 36.3M | 39.8M | 36.9M | 37.6M | 37.7M | 37.7M | 33.7M | 31.8M | 32.0M | 29.5M | 28.8M | Shares out (diluted)Shares |
| $11.60 | $10.95 | $19.09 | $22.91 | $24.56 | $30.30 | $43.36 | $59.23 | $65.88 | $85.69 | $96.74 | Revenue / shareRev/sh |
| $0.37 | $0.98 | $1.98 | $2.67 | $3.86 | $4.82 | $7.29 | $8.88 | $12.63 | $15.28 | $17.09 | EPS (diluted)EPS |
| $2.32 | $2.23 | $3.99 | $5.15 | $6.55 | $6.56 | $10.96 | $12.85 | $18.15 | $23.09 | $25.23 | Owner earnings / shareOE/sh |
| $2.15 | $2.15 | $3.81 | $4.90 | $6.03 | $6.24 | $10.43 | $12.46 | $17.88 | $23.09 | $24.57 | Free cash flow / shareFCF/sh |
| $0.37 | $0.29 | $0.43 | $0.48 | $0.83 | $0.75 | $1.10 | $1.15 | $1.14 | $1.06 | $1.60 | Cap. spending / shareCapex/sh |
| $16.81 | $12.78 | $16.22 | $19.33 | $21.37 | $25.28 | $11.48 | $17.55 | $25.79 | $15.55 | $15.09 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +24.9%/yr | +28.4%/yr |
| Owner earnings / share | +29.1%/yr | +28.7%/yr |
| EPS | +51.2%/yr | +31.7%/yr |
| Capital spending / share | +12.3%/yr | +5.0%/yr |
| Book value / share | −0.9%/yr | −6.2%/yr |
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned $451M of profit into $682M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $451M | $404M | $283M | $245M | $182M |
| Depreciation & amortizationnon-cash charge added back | +$27M | +$28M | +$24M | +$19M | +$16M |
| Stock-based compensationreal costnon-cash, but a real cost | +$35M | +$26M | +$21M | +$21M | +$14M |
| Working capital & othertiming of cash in and out, other non-cash items | +$200M | +$151M | +$106M | +$102M | +$51M |
| Cash from operations | $713M | $609M | $433M | $388M | $263M |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −$31M | −$28M | −$24M | −$19M | −$16M |
| Owner earnings | $682M | $581M | $409M | $369M | $247M |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | −$9M | −$13M | −$18M | −$12M |
| Free cash flow | $682M | $572M | $397M | $351M | $235M |
| Owner-earnings marginowner earnings ÷ revenue | 27% | 28% | 22% | 25% | 22% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $35M), owner earnings is nearer $647M.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- No meaningful interest burdenLittle or no interest expense reported
What this means
Little or no interest expense reported, the business isn't leaning on lenders to operate.
- Net cash, debt-freeCash $497M − debt $0
What this means
Cash and short-term investments exceed every dollar of debt by $497M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Not enough data
What this means
The filing data didn't include the inputs for this check.
Is it a good business?
- Not meaningful hereInvested capital ($38M) = debt $0 + equity $459M − cashIndustry peers: median 9%
What this means
Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.
- High through the cycle10-yr median margin, range 20%–28%; latest $682M = operating cash $713M − maintenance capex $31MIndustry peers: median 11%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 27% of revenue this year, a 22% median across 10 years. Treating stock comp as the real expense it is (less $35M of SBC) leaves $647M.
- Cash-backedCash from ops $713M ÷ net income $451M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Returned more than it generatedDividends + buybacks $917M ÷ Owner Earnings $682M — this fiscal year
What this means
The company returned more than it generated: against $682M of Owner Earnings, $917M (135%) went back to shareholders, $0 dividends, $917M buybacks — the excess came from the balance sheet or borrowing, not the year's operations. Net of $35M stock comp, the real buyback was about $883M. Sustained, that pattern draws down cash or adds debt; the net-debt line above shows where it stands. This year's proportion is 135%; across the record (2016–2025) it is 79%, the capital-allocation section below.
- Investing or harvesting? 1.15×MaintainingCapex $31M ÷ depreciation $27M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
The promise and the pay packet
- Is the buyback buying ownership, or mopping up? 1.4%The count is genuinely shrinkingStock compensation $35M (fiscal 2025), 1.4% of revenue · repurchases $917M · diluted shares -12.3% since 2022
What this means
Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.
Graham’s defensive tests · 3 of 5 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size PassRevenue ≥ $2B · $2.5B
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity MissCurrent ratio ≥ 2× · 0.74×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $0 vs ($354M) WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability PassA profit every year (10-yr record) · no losses
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth PassEarnings +33% over the record · +805%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $13.59/share (latest year $16.16), the averaged base the calculator's gate runs on, and book value is $16.45/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 10 of 10
What this means
Never lost money over the record, the earnings stability Graham insisted on.
- Return on capital ≥ 15% 1 of 4 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 14% → 20% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about 14% early to 20% lately, median 17% — pricing power intact or improving.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Owner earnings growth +25%/yr
What this means
Owner earnings grew about 25% a year over the record.
- Worst year 2016 · 12.5% op. margin
What this means
Stayed profitable even in its hardest year, the resilience that survives recessions.
- Share count −2.3%/yr
What this means
The share count is shrinking, buybacks are quietly growing your slice of the business.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 30, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$503M
- Receivables$442M
- Other current assets$106M
- Accounts payable$38M
- Other current liabilities$1.4B
Its current ratio is below 1, which usually reads as strain; here it is likely structural strength. What it owes in the near term is money to suppliers and customers (payables and deferred revenue), not to lenders, so the balance sheet is funded by operating float, the way Costco's and Amazon's are. The low ratio can be the edge, not the risk; the cash-conversion cycle and the debt due above say which.
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $3.2B of operating cash; how management split it reads as a cash returner, paying most of what it earns straight back to owners.
- Reinvested$260M · 8%
- Buybacks$2.4B · 75%
- Retained (debt / cash)$558M · 17%
- Returned to owners$2.4B
79% of the owner earnings the business produced over the span, $0 as dividends and $2.4B as buybacks.
- Average price paid for buybacks—
Buybacks ran $2.4B over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count−20.8%
The diluted count fell from 36M to 29M, so the buybacks outran the stock issued to staff.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 10-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | August J. Troendle | $5.9M | $7.7M | $247M |
| 2022 | August J. Troendle | $1.9M | $12.9M | $369M |
| 2023 | August J. Troendle | $1.6M | $9.3M | $409M |
| 2024 | August J. Troendle | $8.6M | $17.7M | $581M |
| 2025 | August J. Troendle | $11.4M | $11.7M | $682M |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership20.5%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$35M
The slice of the business handed to employees in shares in fiscal 2025, 1.4% of revenue, equal to 6.5% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
What an owner would ask, FY2025
read the 10-K →- Which reported numbers are a judgment call?Management names Revenue recognition, Income taxes, Stock compensation as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Life Sciences Tools & Services
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| IQVIQVIA Holdings Inc. | $16.3B | — | 9.2% | 5% | 11% |
| ICLRICON plc | $8.3B | 29% | 13.3% | 16% | 13% |
| INCYIncyte | $5.1B | 95% | 15.0% | 24% | 22% |
| CRLCharles River Labs | $4.0B | 84%2y | 14.7% | 9% | 13% |
| ULSUL Solutions Inc. | $3.1B | 48% | 16.2% | 27% | 10% |
| FTREFortrea Holdings Inc. | $2.7B | — | 1.1% | 1% | 5% |
| MEDPMedpace Holdings | $2.5B | — | 17.6% | 27% | 22% |
| NEONeoGenomics Inc. | $727M | 42% | -8.5% | -7% | -4% |
| Group median | — | — | 14.0% | 13% | 12% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Medpace Holdings has delivered.
Medpace Holdings’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.
Through the cycle, Medpace Holdings earns about $559M on its 22.1% median owner-earnings margin. This year’s 26.9% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.
—
9.0% = the 4.68% 10-year Treasury (Jul 30, 2026) + 4.32 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.68%, as of Jul 30, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Free cash flow $707M on 28M shares outstanding, per the 10-Q cover, as of 2026-07-17; net cash $503M. The if-converted diluted count is 29M, 3% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. Capex ($46M) runs well above depreciation ($27M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $721M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← MEC its page in the Manual MEI →
Industry order: ← MDXH the Life Sciences Tools & Services chapter MTD →